1Tas F, Camlica H, Topuz E. Temozolomide in combination with fotemustine in patients with metastatic melanoma[J]. Cancer Chemother Pharmacol, 2008, 62(2): 293-298.
2Trinh VA. Current management of metastatic melanoma[J]. Am J Health Syst Pharm, 2008, 65(24 Suppl 9): $3-$8.
9Hwu WJ, Krown SE, Panageas KS, et al. Temozolomide plus Thalidomide in patients with advanced melanoma: results of a dose- finding trial[J]. J Clin Oncol, 2002, 20(11): 2610-2615.
3D'Amato R J, Loughran MS. Thalidomide is an inhibitor of angiogenesis [J]. Proc Natl Acad Sci USA, 1994,91 (9):4082 - 4085.
4Keifer JA, Guttridge DC, Ashbumer BP, et al. Inhibition of NF - kappa B activity by thalidomide through suppression of IkappaB kinase activity[J]. J Biol Chem, 2001,276(25) :22382 -22387.
5Chapman PB, Einhorn LH, Meyers ML, et al. Phase Ⅲ multi-center randomized trial of the Dartmouth regimen versus dacarbazine in patient with metastatic melanoma [ J]. J Clin Oncol, 1999, 17(9) :2745 -2751.
6Marchand GS, Noiseux N, Tanguay JF , et al. Blockade of in vivo VEGF- mediated angiogenesis by antisense gene therapy :role of Flk21 and Flt21 receptors [J]. Am J Physiol Heart Circ Physiol, 2002,282 ( 1 ) : 194 - 204.
7Valesky M , Spang AJ , Fisher GW, et al. Noninvasive dynamic fluorescence imaging of human melanomas reveals that targeted in hibition of bFGF or FGFR - 1 in melanoma ceils blocks tumor growth by apoptosis [ J ]. Mol Med ,2002,8 ( 2 ) : 103 - 112.
8Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myoloma [ J]. N Engl J Med, 1999, 341 (18) : 1565 - 1571.
9Figg WD,Arlen P, Gulley J, et al. A randomized phase Ⅱ trial of docetaxel (Taxotere?) plus thalidomide in androgen- independent prostate cancer[ J]. Semin Oncol,2001,28 (4 Suppl 15) :62 -66.
10Nathan PD, Gore ME, Eisen TG. Unexpected toxicity of combination thalidomide and interferon a -2a treatment in metastatic renal cell carcinoma[ J]. J Clin Oncol, 2002,20 : 1429 - 1430.
